Abstract：Objective To explore the effecs of different doses of ulinastatin combined with lung-protecting mechanical ventilation on acute lung injury after orthotopic liver transplantation by observing the changes of plasma markers of lung injury and inflammatory mediators.Methods Sixty patients scheduled for liver transplantation under general anesthesia received different doses of ulinastatin combined with the lung-protecting mechanical ventilation strategy. All the patients were randomly divided into three groups: patients in group A were treated with lung-protecting mechanical ventilation alone, group B in which lung-protecting mechanical ventilation was adopted combined with ulinastatin 50,000 U/kg, and group C which was combined with ulinastatin 100,000 U/kg instead. Blood samples were collected from the radial artery for blood gas results and fluid plasma markers of lung injury while bronchoalveolar lavage fluid (BALF) was collected for inflammatory mediators at the following time points: before operation(T1), 3 h in the preanhepatic stage (T2), 2 h (T3)and 4 h in the neohepatic stage (T4). Plasma markers of lung injury, which were clara cell secretory protein 16(CC16), surfactant proteins(SP-D) and soluble receptor for advanced glycation end-products (sRAGE), and inflammatory mediators such as TNF-α and IL-8, were monitored. Moreover, the oxygenation index (PaO2/FiO2,OI), time of tracheal extubation, length of ICU stay and incidence of acute lung injury within one week were recorded.Results Compared with patients in group A, levels of CC16, SP-D and sRAGE in group B and group C were all lower at T3, so was CC16 in group C at T2. In group B, levels of TNF-α at T2 and T4 were lower, so were levels of TNF-α in group C from T2 to T4 and IL-8 at T2 and T4 (P<0.05). Moreover, PaO2/FiO2 (OI) was relatively high in group B at T4, and from T2 to 2 h after operation in group C, where an earlier tracheal extubation and a shorter ICU stay were observed (P<0.05).Conclusions Ulinastatin(100,000 U/kg) combined with the lung-protecting mechanical ventilation strategy may contribute to the protection of lung function in patients for liver transplantation, which can lead to lower levels of plasma markers of lung injury and inflammatory mediators, a higher OI, earlier tracheal extubation and a shorter stay of ICU.
董兰, 王乃田, 陈晓阳, 李占军. 不同剂量乌司他丁联合肺保护性通气对肝移植手术患者的肺保护作用[J]. 武警医学, 2019, 30(6): 513-517.
DONG Lan, WANG Naitian, CHEN Xiaoyang, LI Zhanjun. Effects of different doses of ulinastatin combined with lung-protecting mechanical ventilation on cate lung injury during liver transplantation. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(6): 513-517.
Han S,Mallampalli P K.The role of surfactant in lung disease and host defense against pulmonary infections[J].Ann Am Thorac Soc,2015,12(5):765-774.
[3]
Feng Z,Shi Q,Fan Y,et al.Ulinastatin and/or thymosin α1 for severe sepsis:a systematic review and meta-analysis [J].J Trauma Acute Care,2016,80(2):335-340.
[4]
Bemard G R,Artigas A,Brigham K L,et al.The American-European consensus conference on ARDS, definitions ,mechanisms,relevant outcomes and clinical trial coordination[J].Am J Respir Crit Care Med,1994,149(3):818-824.
[5]
Wright B J.Lung-protective ventilation strategies and adjunctive treatments for emergency medicine patient with acute respiratory failure[J].Emerg Med Clin North Am,2014,32(4):871-887.
Wang L Z,Luo M Y,Zhang J S,et al.Effect of ulinastatin on serum inflammatory factors in Asian patients with acute pancreatitis before and after treatment:a meta-analysis[J].Int J Clin Pharmacol Ther,2016,54(11):890-898.
Mcauley D F,Matthay M A.Clara cell protein CC16:a new lung epithelial biomarker for acute lung injury[J].Chest,2009,135(6): 1408-1410.
[11]
Wutzler S,Lehnert T,Laurer H,et al.Circulating levels of Clara cell protein 16 but not surfactant protein D identify and quantify lung damage injuries[J].J Trauma,2011,71 (2): 31- 36.
Shimizu Y,Sunaga N,Dobashi K,et al.Serum markers in interstitial pneumonia with and without pneumocystis jirovecii colonization:a prospective study[J].BMC Infect Dis,2009,9 (4 ):76-82.
[14]
Uchida T,Shirasawa M,Ware L B,et al.Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury[J].Am J Respir Crit Care Med,2006,173(9):1008-1015.
[15]
Mokra D,Kosutova P.Biomarkers in acute lung injury[J].Respir Physiol Neurobi,2015,209(14):52-58.
[16]
Fagon J Y.Diagnosis and treatment of ventilator-associated pneumonia:fiberoptic bronchoscopy with beonchoalveolar lavage is essential[J]. Semin Respir Crit Care Med,2006,27(1):34-44.
2019, Vol. 30 
